Market revenue in 2024 | USD 42.9 million |
Market revenue in 2030 | USD 156.0 million |
Growth rate | 24.4% (CAGR from 2025 to 2030) |
Largest segment | Gmp grade |
Fastest growing segment | GMP Grade |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | R&D Grade, GMP Grade |
Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 105.83% in 2024. Horizon Databook has segmented the South Korea plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea exhibits high potential for R&D capabilities in the pharmaceutical and biopharmaceutical sectors, which is expected to boost the demand for plasmid DNA products for research purposes. Cancer research has become a national priority for the Korean government.
The Korean government supports several universities, institutions, and researchers to facilitate cancer research activities, which is anticipated to create high demand for pDNA products in the country. Furthermore, increasing R&D investments by major pharmaceutical companies in South Korea are anticipated to create a lucrative environment for market growth.
For instance, in January 2022, Samsung Biologics, a CDMO, intends to begin construction of a new facility (named Plant 5) at Songdo in Incheon, South Korea. The facility will provide multimodal product manufacturing, including cell & gene therapies and viral, plasmid, and mRNA-based next-generation vaccines.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into South Korea plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account